CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 168 enrolled
Drug / intervention
13-valent pneumococcal conjugate vaccine (13vPnC) +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00688870
NCT00688870Phase 3Completed

A PHASE 3, RANDOMIZED, ACTIVE-CONTROLLED, DOUBLE-BLIND TRIAL EVALUATING THE SAFETY, TOLERABILITY AND IMMUNOGENICITY OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS GIVEN WITH ROUTINE PEDIATRIC VACCINATION IN TAIWAN

Wyeth is now a wholly owned subsidiary of Pfizer·interventional·Posted Jun 3, 2008·Updated Oct 7, 2022

In Brief

A Phase 3 clinical trial evaluating 13-valent pneumococcal conjugate vaccine (13vPnC) and 7-valent pneumococcal conjugate vaccine (7vPnC) for Vaccines and Pneumococcal Conjugate Vaccine. Completed, enrolled 168 participants across 2 sites.

Detailed Summary

The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate vaccine (13vPnC), relative to a 7-valent pneumococcal conjugate vaccine (7vPnC) when given concomitantly with routine vaccines in Taiwan.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesTaiwan
Collaborators--

Timeline

Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 3, 2008
Enrollment StartJun 5, 2008
Primary CompletionJan 13, 2010
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 18.1 years ago

Interventions

13-valent pneumococcal conjugate vaccine (13vPnC)biological

13vPnC is given via intramuscular injection at approximately 2, 4, 6, and 15 months of age.

7-valent pneumococcal conjugate vaccine (7vPnC)biological

7vPnC is given via intramuscular injection at approximately 2, 4, 6, and 15 months of age.